← Back to Search

Nonsteroidal Anti-Inflammatory Drug

Single-dose prophylactic indomethacin - SPIN for Premature Birth (SPIN Trial)

Phase 3
Waitlist Available
Led By Souvik Mitra, MD, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Extremely preterm infants born \<26 completed weeks of GA and/or extremely low BW infants born \<750g
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 (±6) months postmenstrual age (pma)
Awards & highlights

Summary

In Canada, about 900 babies each year are born very early (\<26 weeks of gestation) and have a high chance of dying or having a serious bleed in the brain. Families of these extremely preterm babies consider preventing severe brain bleeding as critical to their child's health and well-being. A medicine called indomethacin, when given intravenously in 3-doses, is known to reduce severe brain bleeding. But use of this drug is variable among clinicians working in the neonatal intensive care unit (NICU) due to (a) its side effects on the gut; (b) possible harm when used with other medications; (c) a notion that despite reducing brain bleeds, the child's long-term brain development is not improved. Emerging evidence suggests that a single low-dose indomethacin regimen may be equally effective in reducing severe brain bleeding as compared to a traditional 3-dose regimen. The investigators propose a blinded randomized controlled trial, a study design where babies born \<26 weeks will be randomly assigned within 12 hours of birth to either a single dose of intravenous indomethacin or similar looking placebo in the form a saline solution. The study will test if a single dose indomethacin regimen is effective in improving survival of these babies without the devastating complication of severe brain bleeding. In this study the care providers and researchers will be unaware as to which baby receives indomethacin and which baby receives placebo to ensure no one's expectations or biases can influence the results. The investigators will conduct the study in multiple NICUs across Canada, the United States and Australia and will enroll 500 babies born \<26 weeks or \<750 g birth weight over a period of 3 years. This study will help the investigators determine in the most unbiased way whether a single dose of indomethacin given immediately after birth in the smallest babies born \<26 weeks of gestation can safely and effectively reduce severe brain bleeding.

Who is the study for?
This trial is for extremely preterm infants born at less than 26 weeks of gestation or with a birth weight under 750 grams. The study aims to include about 500 babies from NICUs in Canada, the US, and Australia over three years.
What is being tested?
The trial is testing if a single dose of indomethacin can improve survival without severe brain bleeding compared to a placebo. Babies are randomly assigned to receive either the drug or placebo within 12 hours of birth.
What are the potential side effects?
Indomethacin may cause side effects on the gut and could potentially interact harmfully with other medications used in neonatal care.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 (±6) months postmenstrual age (pma)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 (±6) months postmenstrual age (pma) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Survival without severe intraventricular hemorrhage (sIVH)
Secondary study objectives
Acute kidney injury (AKI)
Chronic pulmonary hypertension
Duration of invasive mechanical ventilation in days
+14 more
Other study objectives
Health Economic outcomes
Pharmacokinetic outcomes

Side effects data

From 2014 Phase 4 trial • 270 Patients • NCT01957215
1%
Vascular rupture
1%
Drug eruption
1%
Gingival bleeding
1%
Application site pruritis
1%
Inflammation
1%
Upper respiratory tract infections
1%
Nasopharyngitis
1%
Ligament sprain
1%
Pruritis
1%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Indomethacin Patch
Placebo Patch

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single-dose prophylactic indomethacin - SPINExperimental Treatment1 Intervention
Infants randomized to the SPIN group will receive a single 0.1 mg/kg dose of intravenous indomethacin within 12h of birth as a slow infusion over 20 mins.
Group II: ControlPlacebo Group1 Intervention
Equal volume saline placebo administered intravenously over 20 mins
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indomethacin
2011
Completed Phase 4
~5790

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,433 Previous Clinical Trials
2,478,939 Total Patients Enrolled
6 Trials studying Premature Birth
1,805 Patients Enrolled for Premature Birth
Souvik Mitra, MD, PhDPrincipal InvestigatorUniversity of British Columbia
~333 spots leftby May 2028